相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
Melanie B. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
Richard S. Finn et al.
LIVER INTERNATIONAL (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells
Bryan C. Fuchs et al.
CANCER RESEARCH (2008)
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
Derek Y. Chiang et al.
CANCER RESEARCH (2008)
Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
Hung Huynh et al.
CLINICAL CANCER RESEARCH (2008)
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine:: A Cancer and Leukemia Group B study
Andreas Neubauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Abby B. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo
Esther Raskopf et al.
JOURNAL OF HEPATOLOGY (2008)
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
Hung Huynh et al.
JOURNAL OF HEPATOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Early Antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma
Andrew X. Zhu et al.
ONCOLOGIST (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Transarterial chemoembolization for patients with hepatocellular carcinoma
Alejandro Forner et al.
HEPATOLOGY RESEARCH (2007)
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
Ronnie T. P. Poon et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
AX Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
Opportunities for targeted therapies in hepatocellular carcinoma
MB Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584
YQ Liu et al.
CANCER RESEARCH (2005)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade
JZ Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma?
WS Moon et al.
MODERN PATHOLOGY (2003)
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery
Y Chao et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
JM Llovet et al.
HEPATOLOGY (2003)
分享论文
